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Abstract
Aims/hypothesis We examined the association of prevalent
and incident cardiovascular disease (CVD) with chronic liver
disease in a cohort of community-based people with type 2
diabetes, in order to clarify the relationship between these two
important conditions.
Methods 1,066 participants with type 2 diabetes aged 60–75
years underwent assessment of a range of liver injury markers
(non-specific injury, steatosis, steatohepatitis, fibrosis, portal
hypertension). Individuals were followed up for incident car-
diovascular events.
Results At baseline there were 370/1,033 patients with prev-
alent CVD, including 317/1,033 with coronary artery disease
(CAD). After a mean follow-up of 4.4 years there were 44/663
incident CVD events, including 27/663 CAD events. There
were 30/82 CVD-related deaths. Risk of dying from or devel-
oping CVDwas no higher in participants with steatosis than in
those without (HR 0.90; 95% CI 0.40, 2.00; p>0.05). The
only notable relationship was with γ-glutamyltransferase
(GGT) (incident CVD: adjusted HR for doubling GGT 1.24
[95% CI 0.97, 1.59] p=0.086; incident CAD: adjusted HR
1.33 [95% CI 1.00, 1.78] p=0.053), suggesting that in our
study population, chronic liver disease may have little effect
on the development of, or mortality from, CVD.
Conclusions/interpretation An independent association
between GGT and CVD warrants further exploration as
a potentially useful addition to current cardiovascular risk pre-
diction models in diabetes. However, overall findings failed to
suggest that there is a clinical or pathophysiological associa-
tion between chronic liver disease and CVD in elderly people
with type 2 diabetes.
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Introduction
Reports of higher cardiovascular mortality rates in people
from the general population with non-alcoholic fatty liver dis-
ease (NAFLD) [1, 2] raise the possibility that there may be a
pathophysiological relationship between NAFLD and the de-
velopment of cardiovascular disease (CVD). In people with
type 2 diabetes, such a relationship could help to explain the
higher prevalences of both conditions. However, the associa-
tion between CVD and NAFLD has not been well researched
in diabetic populations, such that the true relationship between
these two important conditions remains uncertain.
Epidemiological knowledge of the relationship between
NAFLD and CVD in diabetes is particularly limited: current
studies are restricted to ultrasound scan-detected NAFLD and
the secondary care end of the diabetes spectrum [3, 4]. We
therefore aimed to determine the association of CVD with a
range of biomarkers of chronic liver injury in a large cohort
representative of the full spectrum of elderly people with type
2 diabetes.
Biologically, an association between NAFLD and CVD is
plausible. Many of the pathogenic factors proposed for NAFL
D and atherosclerosis are shared (e.g. insulin resistance,
dyslipidaemia, systemic inflammation) and are closely linked
to type 2 diabetes. The concept of the liver–vessel axis hy-
pothesis [5] could also explain the biological mechanisms
linking the liver directly to the accelerated atherosclerosis pro-
posed in NAFLD. There is evidence indicating that a conse-
quence of advanced NAFLD (non-alcoholic steatohepatitis
[NASH]) includes enhanced atherosclerosis via further insulin
resistance leading to atherogenic hyperlipidaemia (low HDL-
cholesterol, high triacylglycerol and high LDL-cholesterol
levels) and systemic inflammation through pro-inflammatory
and pro-atherogenic factors (IL-6, TNF-α, nuclear factor
kappa-light-chain-enhancer of activated B cells [6, 7]).
One of the challenges in exploring the association between
CVD and NAFLD or chronic liver disease in general in
human epidemiological studies is the lack of validated
methods to diagnose the various stages of chronic liver disease
using non-invasive tests which can be ethically applied to
large groups of people who are mostly asymptomatic in terms
of liver disease. Attempts to categorise people as ‘diseased’ or
‘not diseased’ based on findings of such non-invasive tests in
an epidemiological setting are likely to lead to considerable
bias. Therefore, we chose to explore the direct association of a
wide range of different liver injury biomarkers with CVD
rather than attempt to categorise chronic liver disease based
on what would be arbitrary cut-points. We examined the as-
sociation of prevalent and incident CVD with an array of
biomarkers, including those measuring non-specific liver in-
jury (plasma liver enzymes), steatosis (ultrasound),
steatohepatitis (cytokeratin-18 [CK18] [8]), surrogate of ad-
vanced portal hypertension (platelet count), and liver fibrosis
(aspartate to platelet ratio index [APRI] [9], aspartate amino-
transferase [AST] to alanine aminotransferase [ALT] ratio,
fibrosis-4 score [FIB4] [10], enhanced liver fibrosis panel
[ELF] [11] and NAFLD fibrosis score [NFS] [12]).
Methods
The Edinburgh type 2 Diabetes study
Full methods of the Edinburgh Type 2 Diabetes Study
(ET2DS) have been published elsewhere [13]. Patients with
type 2 diabetes aged 60–75 years at baseline were selected at
random from the Lothian Diabetes Register, a comprehensive
register of patients with diabetes living in Lothian, Scotland,
UK. Baseline attendees (n=1,066) have previously been
shown to be representative of all those randomly selected to
participate (n=5,454), and therefore representative of the tar-
get population of older people with type 2 diabetes living in
the general population [14]. The liver assessment clinic was
attended by 939 participants at year 1 (Fig. 1).
Clinical examination
Research clinics were held at the Wellcome Trust Clinical
Research Facility, Western General Hospital, Edinburgh, UK,
at baseline, year 1 and at follow-up and have been described
previously [13, 15]. Briefly, attendees underwent fasting ve-
nous blood sampling for measurement of plasma liver enzymes
(including ALT, AST and γ-glutamyltransferase [GGT]) and
platelets; height and weight recording; blood pressure measure-
ment; and a self-administered questionnaire including standard
questions on current medications (including diabetes treatment,
defined as diet-controlled, oral antihyperglycaemic agent only
or insulin±oral antihyperglycaemic agent), alcohol consump-
tion, smoking (categorised as ever or never), history of liver
disease and CVD, as well as the Edinburgh Claudication and
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WHO chest pain questionnaires. A 12-lead ECG was also re-
corded, using recognised standard operating procedures and a
MAC 1200 resting ECG analysis system (GE Medical
Systems, Milwaukee, Wisconsin, USA), and coded using The
Minnesota Code manual [16]. Imaging included abdominal
ultrasound scan. Average alcohol intake per week over the pre-
vious year and a history of alcohol excess were determined by
questionnaire using questions adapted from the Alcohol Use
Disorders Identification Test Consumption screening tool.
Alcohol excess was defined as >14 units/week in women and
>21 units/week in men [17] or self-reported history of an alco-
hol problem.
NAFLDwas defined as the presence of hepatic steatosis on
ultrasound scan, without alcohol excess or use of hepatotoxic
medication, and a negative liver screen [18].
Alcohol excess was as defined above. Hepatotoxic medi-
cation use was defined as the use of non-topical glucocorti-
coids (isoniazid, methotrexate, amiodarone or tamoxifen) for
>2 weeks within the 6 months prior to ultrasound scan. A
positive liver screening included any of positive autoanti-
bodies (any of anti-nuclear antibody, anti-smooth muscle an-
tibody, anti-mitochondrial antibody), ferritin >2,247 pmol/l,
α-fetoprotein >6 μg/l, or positive hepatitis B or C serology.
Clinically significant positive immunology titres were defined
as anti-smooth muscle antibody titre >1:160 or anti-
mitochondrial antibody titre >1:40 [19].
Biomarkers of chronic liver injury
Biomarkers of liver injury were categorised and defined as:
non-specific liver injury (liver enzyme levels: AST, ALT,
GGT), steatosis (ultrasound scan), steatohepatitis (CK18), liv-
er fibrosis (APRI, AST:ALT ratio, ELF, FIB4 and NFS) and
advanced portal hypertension (platelet count).
Plasma liver enzymes, APRI, AST:ALT ratio, FIB4, NFS
and platelet count were measured at baseline. CK18 and ELF
were measured at year 1. All patients underwent a liver ultra-
sound scan at the 1 year visit. Sonographic grading of hepatic
steatosis was performed using standard criteria, as described
previously, following validation against proton magnetic res-
onance spectroscopy [20].
ALT, AST and GGT were analysed using a Vitros Fusion
chemistry system (Ortho Clinical Diagnostics, High
Wycombe, UK) at the Western General Hospital, Edinburgh,
UK. APRI [9], FIB4 [10] and NFS [12] were calculated as in
the original publications. AST:ALT ratio was calculated as
AST (U/l)/ALT (U/l). CK18 and ELF tests were undertaken
on serum samples taken at the time of the liver ultrasound scan
and subsequently stored at −80°C. CK18 was measured using
the M30-Apoptosense ELISA (Peviva, Stockholm, Sweden)
at the Biomedical Research Unit laboratory, University of
Nottingham, UK. ELF scores were derived from the serum
hyaluronic acid (HA), aminoterminal peptide of procollagen
III (P3NP) and tissue inhibitor of metalloproteinases-1
(TIMP-1) equation as in the original publication [11] and mea-
sured using the ADVIA Centaur immunoassay system
(Siemens Healthcare Diagnostics, New York, NY, USA) at
the iQur laboratory, London, UK.
Given that biomarkers of fibrosis (e.g. ELF) could poten-
tially be influenced by the presence of arthropathies [21] and
renal disease, the presence of joint diseases (osteoarthritis,
rheumatoid arthritis and others) was actively sought through
self-administered questionnaire. Estimated glomerular filtra-
tion rate (eGFR) was measured at the time of clinic attendance
and analysed using a Vitros Fusion chemistry system (Ortho
Clinical Diagnostics) at the Western General Hospital,
Edinburgh, UK.
Identifying CVD
Information on cardiovascular events at baseline and at
follow-up clinics was collected from multiple sources includ-
ing patient- and/or general practitioner-completed question-
naires, 12-lead ECG, and linkage to hospital discharge and
death certification data. Data linkage was undertaken, via the
National Health Service National Services Scotland, to
Scottish Morbidity Record (SMR01) general and acute inpa-
tient discharge records using ICD-10 (www.who.int/
classifications/icd/en/) (and related ICD-9 [www.icd9data.
Baseline participants
n=1,066
Liver substudy participants 
n=939
Data linkage for CV events
n=1,066
ALT, APRI, AST, AST:ALT ratio, FIB4, GGT, 
NFS and platelet count measured n=1,033
CV assessment (questionnaire/ECG/data 
linkage)
CK18 and steatosis measured n=858
ELF measured n=679
CV assessment (questionnaire/ECG/data 
linkage)
Fig. 1 Participant flowchart
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com/2007/Volume1]) codes and to Office for Population
Censuses and Surveys (OPCS) version 4 codes for cardiovas-
cular interventions. A fatal or non-fatal cardiovascular event
was recorded if predetermined criteria based on the multiple
data sources were met.
Myocardial infarction (1) ICD-10 code for myocardial
infarction (MI) on discharge/death record, plus either self-
report of a doctor diagnosis of MI, positive WHO chest pain
questionnaire for MI, report of MI on general practitioner
questionnaire or new ECG codes for MI; or (2) clinical criteria
for MI met following scrutiny of clinical notes.
Angina (1) ICD-10 code for angina as primary diagnosis on
discharge record; or (2) at least two of (a) self-report of a
doctor diagnosis of angina or of starting angina medication,
(b) ECG codes for ischaemia, and (c) positive WHO chest
pain questionnaire; or (3) clinical diagnosis of angina on scru-
tiny of hospital notes.
Stroke (1) ICD-10 code for stroke as discharge/death record;
or (2) clinical criteria for stroke met on scrutiny of clinical
notes in individuals with either self-report of stroke or with
non-primary ICD-10 hospital discharge/death code for stroke.
Transient ischaemic attack (1) ICD-10 code for transient
ischaemic attack (TIA) on discharge record; or (2) clinical
criteria for TIA met on scrutiny of clinical notes in individuals
with either self-report of stroke or with non-primary ICD-10
hospital discharge code for stroke or TIA.
Coronary intervention OPCS-4 code for coronary interven-
tion on discharge record.
Intermittent claudication (1) ICD-10 code for intermittent
claudication on discharge record; or (2) clinical criteria for
intermittent claudication met on scrutiny of clinical notes in
individuals with either self-report of intermittent claudication
or positive Edinburgh Claudication Questionnaire.
Peripheral vascular intervention OPCS-4 code for periph-
eral vascular intervention on discharge record.
Carotid endarterectomy OPCS-4 code for carotid endarter-
ectomy on discharge record.
Prevalent CVD at baseline (for ALT, AST, GGT, AST:ALT
ratio, APRI, FIB4, NFS and platelets) or year 1 (for steatosis,
CK18, ELF) was defined as any of MI, angina, coronary
intervention, intermittent claudication, peripheral vascular
intervention, stroke, TIA or carotid endarterectomy at any
time prior to this point. Prevalent coronary artery disease
(CAD) at baseline/year 1 was defined as any of MI, angina
or coronary intervention at any time.
Incident CVD was defined as any of MI, angina, coronary
intervention, intermittent claudication, peripheral vascular in-
tervention, stroke, TIA or carotid endarterectomy occurring
between baseline/year 1 and end of August 2011, for both
non-fatal and fatal events, in those patients without prevalent
CVD at baseline. Incident CAD was defined as any of MI,
angina or coronary intervention occurring between baseline/
year 1 and end of August 2011, for non-fatal and fatal events,
in those patients without prevalent CAD at baseline.
Data analysis
The primary outcome measures were prevalent cardiovascular
events and incident cardiovascular events. The secondary out-
come measures were prevalent and incident CAD events.
Fatal and non-fatal events were combined for analysis.
Data were assessed for normality and where necessary non-
normal variables (APRI, CK18 and GGT) were transformed
on the log2 scale.
The follow-up time for each individual for incident disease
was from the date of the baseline/liver substudy research clinic
attendance until the first of: cardiovascular event, death or end
of August 2011.
Analysis was undertaken using a listwise approach for
three scenarios—measurements taken at baseline (ALT,
APRI, AST, AST:ALT ratio, FIB4, GGT, NFS and platelets),
measurements taken at the initial liver substudy clinic (CK18
and steatosis on ultrasound scan) and ELF.
Univariate analysis with normal continuous variables was
carried out using Student’s t test (ALT, AST, AST:ALT ratio,
ELF FIB4, NFS and platelets), non-normal continuous vari-
ables (APRI, CK18 and GGT) using the Mann–Whitney U
test, and categorical variables (steatosis) using the χ2 test,
examining for both the presence of prevalent and incident
CVD and CAD.
Logistic regression for the association with prevalent CVD
and CAD, and Cox proportional hazards regression for the
association with incident CVD and CAD, were undertaken
for all markers of liver injury. Both were performed unadjust-
ed, adjusted for age and sex, and additionally adjusted for age,
sex, duration of diabetes, treatment of diabetes, lipid-lowering
drugs, blood pressure-lowering drugs, deprivation (Scottish
Index of Multiple Deprivation quintile), smoking status,
excess alcohol consumption, BMI, systolic blood pressure
(sBP), diastolic blood pressure (dBP), HbA1c, HDL-cholester-
ol, total cholesterol and eGFR. Analysis of prevalent disease
was undertaken for all participants; analysis of incident dis-
ease was undertaken for participants free of CVD at baseline.
Sensitivity analyses of the incident cardiovascular events
were undertaken: (1) for participants with NAFLD (defined as
the presence of hepatic steatosis on ultrasound scan without
alcohol excess or use of hepatotoxic medication and a
Diabetologia (2015) 58:1484–1493 1487
negative liver screen); and (2) following inclusion of all par-
ticipants and adjusted for prevalent CVD at baseline.
Data were analysed using SPSS version 19.0 (SPSS,
Chicago, IL, USA).
Ethics approval was obtained from the Lothian Research
Ethics Committee and all participants gave written informed
consent.
Results
Patient characteristics
The baseline research clinic was attended by 1,066 patients,
939 (88%) of whom returned for the liver assessment at 1 year.
Figure 1 shows the participant flow. There were no significant
differences between attenders at baseline and attenders at the
liver assessment (reported previously [22]); participant char-
acteristics are described in Table 1.
Full data from baseline were available for 1,033 partici-
pants. From the 1 year liver assessment, steatosis and CK18
data were available for 858 participants. ELF data were avail-
able on a random subgroup of 679 participants; there were no
significant differences between participants with and without
available ELF scores (Table 1).
Prevalent CVD
At baseline there were 370/1,033 (35.8%) patients with prev-
alent CVD and 317/1,033 (30.7%) with prevalent CAD. A
significantly higher proportion of those with CVD and CAD
were male (both 61.8%, p<0.001) compared with those free
of disease. Those with CVD and CAD were older (mean 68.4
vs 67.6 years, p=0.004, and 68.6 vs 67.6 years, p<0.001,
respectively) than those without. Results were similar for the
1 year assessment: at baseline there were 303/858 (35.3%)
patients with prevalent CVD and 260/858 (30.3%) with prev-
alent CAD. Again, those with CVD and CAD were signifi-
cantly more likely to be male and to be older than those
without.
There were no significant differences in the distribution of
joint disease potentially influencing fibrosis biomarkers be-
tween those with and those without CVD (osteoarthritis
22.3% vs 23.8%, p=0.785; rheumatoid arthritis 5.3% vs
3.2%, p=0.173; other joint disease 15.6% vs 12.5%, p=
0.440, respectively). Mean eGFR was lower in those with
preva len t CVD than in those wi thou t (62 .1 vs
65.7 ml−1 min−1 1.73 m−2, p<0.001).
Participants with prevalent CVD had marginally lower
ALT (mean 41.9 vs 43.7 U/l, p=0.048) and higher GGT mea-
sures (median 20.0 vs 17.0 U/l, p<0.001) compared with
Table 1 Characteristics of all
ET2DS participants, those under-
going CK18 and steatosis assess-
ment and subgroups with ELF
measurements
Characteristic All participants
(n=1,033)
CK18 and steatosis
participants
(n=858)
ELF participants
(n=679)
Age, years 67.9 (4.2) 67.9 (4.2) 67.8 (4.2)
Sex, % male 51.2 (530) 53.8 (462) 52.6 (357)
Duration of diabetes, years 6.0 (3.0–11.0) 6.0 (3.0–11.0) 6.0 (3.0–10.0)
HbA1c, % 7.39 (1.1) 7.38 (1.1) 7.36 (1.1)
HbA1c, mmol/mol 57.0 (12.1) 57.2 (12.3) 57.0 (11.9)
Fasting glucose, mmol/l 7.54 (2.1) 7.48 (2.0) 7.49 (2.0)
Diet-controlled, % yes 19.8 (197) 19.3 (161) 19.2 (127)
Oral antihyperglycaemic agent use, % yes 63.0 (628) 64.8 (541) 65.4 (432)
Insulin therapy, % yes 17.3 (172) 15.9 (133) 15.4 (102)
BMI, kg/m2 31.3 (5.6) 31.2 (5.7) 31.2 (5.7)
Waist circumference, cm 106.7 (12.7) 106.6 (12.8) 106.5 (12.7)
Serum cholesterol, mmol/l 4.30 (0.9) 4.31 (0.9) 4.33 (0.9)
sBP, mmHg 133.2 (16.4) 133.3 (16.1) 133.5 (16.3)
dBP, mmHg 69.1 (9.0) 69.3 (8.9) 69.4 (8.9)
Alcohol excessa, % yes 8.1 (84) 7.6 (65) 8.4 (57)
Ever smoked, % yes 60.7 (527) 59.6 (455) 60.0 (366)
Values are mean (SD), median (interquartile range) or proportion (n)
All variables were measured concurrently at year 1 examination of the ET2DS, except for BMI and waist
circumference, which were measured at baseline
a Defined as women >14 units/week, men >21 units/week or patient disclosed history of a current or prior alcohol
problem
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those without. Patients with prevalent CAD also had signifi-
cantly higher GGT values than those without (median 20.0 vs
17.0U/l, p<0.001), although all median levels were within the
normal range. The proportion of participants with steatosis
was lower in those with CVD than in those without (CVD
54.1% vs 57.5%, p=0.350; CAD 51.2% vs 58.5%, p=
0.051). Full data are given in Table 1 of the electronic supple-
mentary material (ESM).
Multivariable analysis of the relationship between liver
markers and prevalent cardiovascular events, adjusting for
age, sex, duration of diabetes, treatment of diabetes, lipid-
lowering drugs, blood pressure-lowering drugs, deprivation,
smoking status, excess alcohol consumption, BMI, systolic
blood pressure, HbA1c, HDL-cholesterol, total cholesterol
and eGFR, is shown in Table 2. GGT was the only liver
marker independently associated with prevalent CVD
(OR for a doubling of GGT 1.18; 95% CI 1.03, 1.36;
p=0.021) or CAD (OR 1.21; 95% CI 1.05, 1.40; p=0.008).
Incident CVD
There were 663 participants without CVD. After a mean
follow-up of 4.4 years from baseline attendance there were
44/663 (6.6%) patients with incident CVD and 27/663
(4.1%) with incident CAD events. A significantly higher pro-
portion of those with incident CVD were male (59.1% vs
44.3%, p=0.061) and they were significantly older (68.9 vs
67.5 years, p=0.024), with no differences in those with
incident CAD compared with those without incident
CAD. Similar results were obtained for those patients
followed up from the 1 year assessment (mean follow-
up 3.5 years), with 35/561 (6.2%) incident CVD and
19/561 (3.4%) incident CAD events and with a similar
age/sex distribution.
There were 82/1,033 (7.9%) deaths in the follow-up period
from baseline, with 30/82 (36.6%) attributable to CVD, of
which 20 were attributable to CAD.
Table 2 Multivariable association between liver markers and prevalent cardiovascular events
Liver marker Model 1 p value Model 2 p value Model 3 p value
All CVD
ALT, U/l 0.99 (0.98, 1.00) 0.079 0.99 (0.98, 1.00) 0.028 0.99 (0.98, 1.00) 0.088
AST, U/l 0.99 (0.98, 1.01) 0.341 0.99 (0.98, 1.01) 0.174 0.99 (0.98, 1.01) 0.385
GGT, log2
a 1.21 (1.07, 1.37) 0.002 1.20 (1.06, 1.35) 0.005 1.18 (1.03, 1.36) 0.021
Steatosis, % yes 0.91 (0.68, 1.22) 0.518 0.96 (0.71, 1.30) 0.774 0.84 (0.60, 1.17) 0.296
CK18, log2
a 1.08 (0.90, 1.30) 0.421 1.09 (0.90, 1.31) 0.405 0.99 (0.81, 1.22) 0.926
APRI, log2
a 0.98 (0.78, 1.23) 0.833 0.85 (0.67, 1.08) 0.189 0.90 (0.70, 1.67) 0.439
AST:ALT ratio 1.34 (0.56, 3.21) 0.509 1.39 (0.56, 3.44) 0.473 1.51 (0.56, 4.07) 0.419
ELF score 1.00 (0.83, 1.21) 0.984 1.01 (0.82, 1.23) 0.964 0.94 (0.74, 1.19) 0.604
FIB4 1.13 (0.90, 1.41) 0.289 1.01 (0.80, 1.28) 0.921 1.03 (0.80, 1.33) 0.801
NFS 1.09 (0.96, 1.24) 0.174 1.07 (0.93, 1.22) 0.350 1.01 (0.85, 1.19) 0.915
Platelets, ×109/l 1.00 (1.00, 1.00) 0.569 1.00 (1.00, 1.00) 0.499 1.00 (1.00, 1.00) 0.734
CAD
ALT, U/l 0.99 (0.98, 1.00) 0.200 0.99 (0.98, 1.00) 0.124 0.99 (0.98, 1.01) 0.390
AST, U/l 0.99 (0.98, 1.01) 0.383 0.99 (0.98, 1.01) 0.230 1.00 (0.98, 1.01) 0.588
GGT, log2
a 1.22 (1.08, 1.39) 0.002 1.22 (1.07, 1.38) 0.002 1.21 (1.05, 1.40) 0.008
Steatosis, % yes 0.75 (0.55, 1.02) 0.064 0.79 (0.58, 1.08) 0.140 0.66 (0.46, 0.94) 0.019
CK18, log2
a 1.05 (0.86, 1.28) 0.650 1.05 (0.86, 1.28) 0.610 0.96 (0.78, 1.18) 0.707
APRI, log2
a 1.00 (0.79, 1.27) 0.987 0.88 (0.67, 1.13) 0.320 0.95 (0.73, 1.24) 0.720
AST:ALT ratio 1.01 (0.40, 2.53) 0.981 0.93 (0.36, 2.42) 0.887 0.94 (0.33, 2.66) 0.912
ELF score 0.98 (0.80, 1.20) 0.848 0.96 (0.77, 1.19) 0.726 0.88 (0.69, 1.13) 0.324
FIB4 1.20 (0.95, 1.50) 0.123 1.07 (0.84, 1.36) 0.599 1.11 (0.85, 1.43) 0.441
NFS 1.11 (0.97, 1.27) 0.138 1.07 (0.93, 1.23) 0.328 1.03 (0.86, 1.22) 0.765
Platelets, ×109/l 1.00 (1.00, 1.00) 0.386 1.00 (1.00, 1.00) 0.788 1.00 (1.00, 1.00) 0.967
Values are ORs (95% CI)
a APRI, CK18 and GGT analysed on the log2 scale for linearisation; therefore, ORs relate to a doubling of the marker
Model 1, unadjusted; model 2, adjusted for age and sex; model 3, adjusted for age, sex, duration of diabetes, treatment of diabetes, lipid-lowering drugs,
blood pressure-lowering drugs, deprivation (Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol consumption, BMI, sBP,
dBP, HbA1c, HDL-cholesterol, total cholesterol and eGFR at baseline
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Mean (or median) liver injury marker levels were largely
similar between participants with and without incident CVD
(ESM Table 2) and after multivariable adjustment (Table 3).
Only GGT appeared to have some independent association
with either incident CVD (HR for a doubling of GGT 1.24;
95%CI 0.97, 1.59; p=0.086) or incident CAD (HR 1.33; 95%
CI 1.00, 1.78; p=0.053). None of the individual covariables
added to the multivariable model had a major attenuating ef-
fect on the HR estimating the GGT–outcome association
(ESM Table 3). In further analyses performed on all partici-
pants with either a first or subsequent cardiovascular event
occurring after baseline (i.e. including those with prevalent
CVD at baseline, but with adjustment for prevalent cases),
an association between GGT and events was confirmed
(ESM Tables 4 and 5). HRs with similar magnitudes were
observed with increased statistical significance ( p<0.05),
likely due to the increase in sample size.
When restricted to patients with NAFLD (n=319) there
were 38 incident cardiovascular events, with 23 attributable
to CAD. Of all the liver injury markers investigated, GGT
alone showed an independent association with incident CVD
in this subgroup (fully adjusted HR for a doubling of GGT
1.56; 95% CI 1.08, 2.28; p=0.019) (ESM Tables 6 and 7).
Discussion
In this large-scale epidemiological study, we have shown that
raised GGT is independently associated with an increase in
both prevalent and incident cardiovascular events in older
people with type 2 diabetes. Previous studies, predominantly
in younger samples of the general population, have found
similar results for this plasma liver enzyme; we have now
shown that findings are consistent in a high-risk (diabetic)
and older subgroup of the population. Despite the availability
of a wide range of other liver injury markers, we found no
evidence that markers of hepatic steatosis, steatohepatitis, por-
tal hypertension or fibrosis were associated with higher levels
Table 3 Multivariable association between liver markers and any incident CVD events
Liver marker Model 1 p value Model 2 p value Model 3 p value
All CVD
ALT, U/l 1.00 (0.97, 1.02) 0.754 1.00 (0.97, 1.02) 0.836 0.99 (0.97, 1.02) 0.669
AST, U/l 1.01 (0.98, 1.04) 0.526 1.01 (0.98, 1.04) 0.544 1.01 (0.97, 1.04) 0.700
GGT, log2
a 1.25 (0.99, 1.59) 0.062 1.26 (0.99, 1.60) 0.059 1.24 (0.97, 1.59) 0.086
Steatosis, % yes 0.78 (0.36, 1.67) 0.525 0.84 (0.39, 1.80) 0.654 0.90 (0.40, 2.00) 0.787
CK18, log2
a 1.05 (0.64, 1.70) 0.857 1.13 (0.68, 1.85) 0.643 1.02 (0.60, 1.75) 0.931
APRI, log2
a 0.88 (0.505, 1.525) 0.644 0.79 (0.43, 1.46) 0.448 0.76 (0.40, 1.45) 0.408
AST:ALT ratio 3.63 (0.61, 21.61) 0.156 2.85 (0.475, 17.06) 0.252 3.58 (0.53, 28.12) 0.183
ELF score 1.220 (0.91, 1.64) 0.185 1.19 (0.85, 1.66) 0.312 1.15 (0.81, 1.64) 0.443
FIB4 1.01 (0.54, 1.91) 0.966 0.82 (0.40, 1.68) 0.586 0.83 (0.39, 1.76) 0.625
NFS 0.81 (0.58, 1.14) 0.226 0.76 (0.54, 1.06) 0.109 0.78 (0.57, 1.09) 0.143
Platelets, ×109/l 1.00 (1.00, 1.01) 0.162 1.01 (1.00, 1.01) 0.061 1.00 (1.00, 1.01) 0.110
CAD
ALT, U/l 1.00 (0.98, 1.03) 0.771 1.01 (0.98, 1.04) 0.497 1.01 (0.98, 1.04) 0.611
AST, U/l 1.02 (0.99, 1.05) 0.213 1.03 (0.99, 1.06) 0.135 1.02 (0.99, 1.06) 0.220
GGT, log2
a 1.27 (0..95, 1.69) 0.103 1.31 (9.88, 1.75) 0.060 1.33 (1.00, 1.78) 0.053
Steatosis, % yes 0.82 (0.32, 2.14) 0.688 0.87 (0.33, 2.27) 0.774 0.91 (0.33, 2.53) 0.858
CK18, log2
a 1.07 (0.58, 1.99) 0.822 1.10 (0.60, 2.01) 0.748 0.96 (0.49, 1.90) 0.908
APRI, log2
a 1.07 (0.56, 2.06) 0.839 1.15 (0.56, 2.34) 0.709 1.10 (0.52, 2.32) 0.804
AST:ALT ratio 4.36 (0.51, 37.18) 0.178 3.40 (0.37, 31.13) 0.278 4.25 (0.39, 46.73) 0.237
ELF score 1.24 (0.85, 1.80) 0.269 1.15 (0.76, 1.74) 0.508 1.12 (0.69, 1.82) 0.642
FIB4 1.28 (0.64, 2.60) 0.486 1.22 (0.57, 2.64) 0.611 1.25 (0.56, 2.79) 0.583
NFS 0.84 (0.55, 1.28) 0.416 0.81 (0.53, 1.23) 0.323 0.76 (0.51, 1.17) 0.225
Platelets, ×109/l 1.00 (1.00, 1.01) 0.301 1.00 (1.00, 1.01) 0.286 1.00 (1.00, 1.01) 0.297
Values are HRs (95% CI)
a APRI, CK18 and GGT analysed on the log2 scale for linearisation; therefore, ORs relate to a doubling of the marker
Model 1, unadjusted; model 2, adjusted for age and sex; model 3, adjusted for age, sex, duration of diabetes, treatment of diabetes, lipid-lowering drugs,
blood pressure-lowering drugs, deprivation (Scottish Index of Multiple Deprivation quintile), smoking status, excess alcohol consumption, BMI, sBP,
dBP, HbA1c, HDL-cholesterol, total cholesterol and eGFR at baseline
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of prevalent or incident CVD, suggesting that liver disease
may have little effect on the development of vascular compli-
cations in our study population.
A major strength of this study is its representation of the
full spectrum of people with type 2 diabetes, not just those
attending secondary care or receiving advanced treatment mo-
dalities. This population is of particular interest as it may show
an accelerated progression of liver disease due to the com-
bined effects of age and metabolic risk factors. Community-
based populations of people with type 2 diabetes represent the
vast majority of all people with type 2 diabetes and, as such,
require special attention given the impact of their longer term
care on health service provision.
Our findings are consistent with previous findings of a
significant association between GGT and both prevalent and
incident CVD in the general population [3, 23–30], contribut-
ing to the paucity of literature in diabetic populations. In ad-
dition, contrary to previous findings, we found that this asso-
ciation persists into older age [26], independently of a wide
range of cardiovascular risk factors. There is a biological plau-
sibility for this relationship: GGT degrades glutathione to glu-
tamate, which via cysteinylglycine is involved in iron reduc-
tion, allowing lipoprotein oxidation within atheromatous
plaques [31]. What is unclear is whether GGT is a pathogenic
factor in atherogenesis or simply a surrogate biomarker of the
microinflammatory, plaque-associated inflammatory re-
sponse. Given that no liver injury markers other than GGT
were independently associated with CVD, this strengthens
the argument for the GGTassociation being driven by system-
ic inflammation as opposed to a direct consequence of chronic
liver disease. Whatever the underlying mechanism, our find-
ings indicate that further investigation is warranted into
whether or not GGT could add predictive ability to existing
vascular risk prediction models in type 2 diabetes [32].
In terms of the association between CVD and other liver
injury markers, previous studies are limited and inconclusive.
Significant associations between transaminases and both in-
creased and decreased CVD in the general population have
been reported [33, 34]. Investigations into the relationship
between NAFLD (defined as the presence of hepatic steatosis
on ultrasound scan) and cardiovascular events [35, 36], in
populations comprised exclusively of patients with type 2 di-
abetes [3, 4, 37, 38], have reported significant associations
between NAFLD and incident CVD (OR 1.53 [3], HR 1.96
[38], after controlling for cardiovascular risk factors), but no
association with liver enzymes (including GGT). Although
the present study failed to find a similar relationship between
sonographic hepatic steatosis and CVD, our cohort differs
from diabetic cohorts studied previously, mainly in its broad
spectrum of patients with type 2 diabetes. Targher et al used a
study population derived exclusively from secondary care di-
abetes settings (therein limiting generalisability), where the
influence of hepatic steatosis may be stronger in the context
of more severe diabetes, consistent with other studies looking
at more general populations and cardiovascular mortality [37].
Whilst our findings may also be affected by specific cohort
effects, the size and follow-up time are comparable to those of
several other similar studies [3, 26].
Our finding of a lower prevalence of CVD in people with
steatosis could be explained, at least in part, by regression of
hepatic steatosis with advancing liver disease [39]; or it may
reflect survival bias, in that those with the most severe
NAFLD had already died prior to participation in the ET2DS.
In patients with NAFLD, relative concentrations of serum
CK18 can discriminate between steatosis and NASH [8].
However, there are no previous studies examining the rela-
tionship between CK18 levels and cardiovascular events in
either general or diabetic populations. Several previous studies
diagnosing NASH using different methods (such as biopsy or
elevated ALT levels) showed mixed results for the association
with cardiovascular risk (e.g. risk scores, lipid levels). Both
Soderberg et al [40] and Ekstedt et al [2] found associations of
all-cause and cardiovascular mortality with the presence of
biopsy-proven NASH, but no association with steatosis.
Conversely, Lazo et al [41] found no association between
NASH and cardiovascular mortality in patients diagnosed by
ultrasound scan and elevated hepatic enzymes, suggesting that
the criteria for NAFLD and NASH classification may have a
significant impact on findings.
Data on the relationship between hepatic fibrosis and CVD
are also limited. Kim et al found significant associations be-
tween the NFS, APRI and FIB4 with cardiovascular mortality
in a general population [42]. Our study used all these, as well
as the ELF score, an extracellular matrix-related multi-com-
ponent panel (HA, P3NP and TIMP-1), validated for use in
patients with NAFLD [20], and found no relationship.
It should be noted that the utility of different liver injury
biomarkers may be determined by the context in which they
are used. For example, there is a body of evidence validating
non-invasive liver biomarkers for the cross-sectional stratifica-
tion of liver disease in secondary care and predicting future
liver-related clinical outcomes [43, 44]. Results from this study
do not suggest that most of the markers investigated would add
prognostic value to existing risk scores used to predict cardio-
vascular endpoints in diabetes [32]. The exception to this is
GGT, which is generally not considered useful for stratifying
active liver disease, but which may prove beneficial in
predicting CVD. Given the results presented here, further in-
vestigation into this question in diabetes is warranted.
The strengths and limitations of this study should be ac-
knowledged. The large size, population-based approach, pro-
spective design with intensive investigation for incident car-
diovascular events, and wide range of liver biomarkers inves-
tigated are key strengths of the current study. The modest
follow-up duration is partially offset by the large sample size,
resulting in a significant number of person-years at risk, and
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by the high-risk population under study, which resulted in a
high number of incident events. Without a liver biopsy it is not
currently possible to accurately identify NAFLD. However,
we believe that our comprehensive approach of using ultra-
sound scan, assessment of alcohol consumption and hepato-
toxic medication use, and liver screen will identify the vast
majority of patients with NAFLD, potentially missing only
those with minimal hepatic steatosis due to regression of
steatosis in the advanced stages of the disease process.
In conclusion, our study provides evidence that GGT may
independently associate with CVD and that its potential prog-
nostic value for CVD in people with type 2 diabetes would be
usefully investigated. However, lack of association between
CVD and other markers of liver injury (non-specific injury,
steatosis, steatohepatitis, significant portal hypertension,
fibrosis) suggests that chronic liver disease per se may not
have a major influence on the development of CVD, at least
in older diabetic populations.
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